NAV

Lorajmine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lorajmine
DrugBank Accession Number
DB13651
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 402.92
Monoisotopic: 402.1710204
Chemical Formula
C22H27ClN2O3
Synonyms
  • Lorajmine

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcebutololAcebutolol may increase the arrhythmogenic activities of Lorajmine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Lorajmine.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Lorajmine.
AdenosineAdenosine may increase the arrhythmogenic activities of Lorajmine.
AjmalineAjmaline may increase the arrhythmogenic activities of Lorajmine.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Lorajmine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Lorajmine.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Lorajmine.
AmifampridineThe risk or severity of QTc prolongation can be increased when Lorajmine is combined with Amifampridine.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Lorajmine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
C01BA12 — Lorajmine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as ajmaline-sarpagine alkaloids. These are organic compounds containing either of the ajmalan, sarpagan skeleton, or derivative thereof. The Sarpagine (Akuammidine) group, based on the sarpagan nucleus, arises from bond formation between C-16 and C-5 of the corynantheine precursor. Ajmaline alkaloids are based on a 17,19-secoyohimban skeleton (oxayohimban) which is invariably present as an ether.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ajmaline-sarpagine alkaloids
Sub Class
Not Available
Direct Parent
Ajmaline-sarpagine alkaloids
Alternative Parents
Beta carbolines / Quinolizidines / Quinuclidines / Dialkylarylamines / Aralkylamines / Azepanes / Piperidines / Benzenoids / Alpha-halocarboxylic acid derivatives / Amino acids and derivatives
show 9 more
Substituents
Alkanolamine / Alkyl chloride / Alkyl halide / Alpha-halocarboxylic acid derivative / Alpha-halocarboxylic acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
F96VX65849
CAS number
47562-08-3
InChI Key
LAHDERDHXJFFJU-ZWNKPRIXSA-N
InChI
InChI=1S/C22H27ClN2O3/c1-3-11-12-8-15-19-22(13-6-4-5-7-14(13)24(19)2)9-16(25(15)21(11)27)18(12)20(22)28-17(26)10-23/h4-7,11-12,15-16,18-21,27H,3,8-10H2,1-2H3/t11-,12-,15-,16-,18-,19-,20+,21+,22+/m0/s1
IUPAC Name
(1R,9R,10S,12R,13S,14R,16S,17S,18R)-13-ethyl-14-hydroxy-8-methyl-8,15-diazahexacyclo[14.2.1.0^{1,9}.0^{2,7}.0^{10,15}.0^{12,17}]nonadeca-2,4,6-trien-18-yl 2-chloroacetate
SMILES
CC[C@@H]1[C@@H](O)N2[C@H]3C[C@]45[C@H](OC(=O)CCl)[C@H]3[C@H]1C[C@H]2[C@@H]4N(C)C1=CC=CC=C51

References

General References
Not Available
ChemSpider
34990507
ChEBI
135646
ZINC
ZINC000056897614
Wikipedia
Lorajmine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.438 mg/mLALOGPS
logP2.96ALOGPS
logP2.83Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)13.33Chemaxon
pKa (Strongest Basic)7.27Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area53.01 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity106.47 m3·mol-1Chemaxon
Polarizability42.62 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:46 / Updated at February 21, 2021 18:54